Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending January 2014. The report serves as a notification of transactions involving directors, persons discharging managerial responsibility (PDMRs), or connected persons, specifically regarding the GlaxoSmithKline 2009 Performance Share Plan.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on share plan transactions.
- Share Price (Ordinary Shares): 1597.50 pence
- Share Price (ADS): $52.84
- Transaction Type: Notional re-investment of dividends paid on January 9, 2014.
Material Changes
The filing details increases in notional interests for specific individuals following the dividend re-investment:
- Dr M M Slaoui: Connected person Dr K Slaoui received an increase of 45.455 ADSs.
- Mr P C Thomson: Connected person Mrs K Thomson received an increase of 75.822 Ordinary Shares.
No material changes to the company's financial position or operations are reported in this document.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is a regulatory disclosure of director share plan activity in accordance with Disclosure and Transparency Rule 3.1.4R(1)(c).
Key Facts for Investor Verification
- Verify the vesting conditions of the 2009 Performance Share Plan to understand when notional dividends will be paid out.
- Confirm the total number of shares held by Dr M M Slaoui and Mr P C Thomson to assess the significance of these notional increases.
- Check subsequent filings for actual financial performance data, as this 6-K contains no operational or financial results.